BioSpace News Archive

Salarius Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, announced that it will effect a 1-for-8 reverse stock split at 5:00 p.m. Eastern Time, on June 14, 2024.

STRATA Skin Sciences, Inc. announces the availability of two virtual webinars that discuss the benefits of using its XTRAC® excimer device for the treatment of psoriasis, vitiligo, and eczema and its TheraClear®X photopneumatic device for the treatment of mild to moderate acne.

Science 37 Holdings, Inc., a leader in enhancing patient access to clinical trials, announced the final enrollment figures from its 20-month engagement with a clinical-stage drug development company advancing novel small molecule therapeutics for systemic neuro-immune disorders.

Quoin Pharmaceuticals Ltd., a specialty pharmaceutical company focused on rare and orphan diseases, announced that it has signed a research agreement with The School of Pharmacy at University College Cork, Ireland.

Recce Pharmaceuticals Ltd., the Company developing a new class of synthetic anti-infectives, announced it completed dosing an additional cohort in its Phase I/II UTI/Urosepsis trial, evaluating RECCE® 327 at fast infusion rates.

Milestone Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, announced that it will host Part I of its virtual investor educational series on Thursday, June 20, 2024, at 8:00 AM ET.

Fulcrum Therapeutics, Inc.® announced upcoming presentations to be made at the 31st Annual FSHD Society International Research Congress being held June 13-14, 2024 in Denver, Colorado, including an abstract outlining the baseline characteristics of patients enrolled in the Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy.

PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”),VERSATILE-002 is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today provided a data update from its ongoing VERSATILE-002 Phase 2 clinical trial.

Triveni Bio Inc. announced that Bhaskar Srivastava, M.D., Ph.D., has joined the company as Chief Medical Officer.

DiamiR Biosciences announced that the company’s co-founder Dr. Kira Sheinerman will present at the 2024 International Rett Syndrome Foundation Rett Syndrome Scientific Meeting, taking place June 18-19, 2024, in Westminster, CO.